Boston Scientific (BSX) EBT (2009 - 2026)

Boston Scientific (BSX) has 18 years of EBT data on file, last reported at $1.2 billion in Q1 2026.

• For the quarter ending Q1 2026, EBT rose 44.35% year-over-year to $1.2 billion; the trailing twelve-month figure through Mar 2026 stood at $3.7 billion (up 50.95% YoY), and the FY2025 full-year result was $3.4 billion, up 48.33% from the prior year.
• EBT grew to $1.2 billion in Q1 2026, from $700.0 million in the prior quarter.
• In the past five years, EBT ranged from a high of $1.2 billion in Q1 2026 to a low of $156.0 million in Q1 2022.
• A 5-year average of $585.6 million and a median of $585.0 million in 2024 frame the typical range for EBT.
• Peak annual rise in EBT reached 232.77% in 2022, while the deepest fall reached 52.0% in 2022.
• Tracing BSX's EBT over 5 years: stood at $396.0 million in 2022, then grew by 27.53% to $505.0 million in 2023, then rose by 15.84% to $585.0 million in 2024, then gained by 19.66% to $700.0 million in 2025, then soared by 66.0% to $1.2 billion in 2026.
• Business Quant data shows BSX's EBT at $1.2 billion in Q1 2026, $700.0 million in Q4 2025, and $939.0 million in Q3 2025.